​​​​​​​Morp

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Conference11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement.MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatme...

Related Keywords

Delaware , United States , Germany , Boston , Massachusetts , Georgia , Munich , Bayern , Atlanta , American , Grzegorz Nowakowski , Peter Langmuir , Nuwan Kurukulasuriya , Tafasitamab Monjuvi , Practice Research Clinical Haematology , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Xencor Inc , Group Vice , Drug Administration , Global Head Of Medical Affairs , Janssen Research Development , Morphosys Us Inc , Nasdaq , Distribution Services , Exchange Commission , Meeting Of The Society Hematologic Oncology , European Medicines Agency , Refractory Diffuse Largeb Cell , Hematologic Oncology , American Society , Hematology Annual Meeting , Mayo Clinic , Senior Vice President , Global Head , Medical Affairs , Group Vice President , Oncology Targeted Therapies , Diffuse Largeb Cell Lymphoma , National Comprehensive Cancer , European Society , Medical Oncology , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Janssen Research , Janssen Biotech , Morphosy Annual Report , Practice Research , Corporate News , Regulatory Announcements ,